Market Overview

Daré Bioscience Rallies On FDA Designation For Bacterial Vaginosis Drug

Daré Bioscience Rallies On FDA Designation For Bacterial Vaginosis Drug

Shares of the thinly-traded, nano-cap penny stock Daré Bioscience Inc (NASDAQ: DARE) were trading higher Monday. 

What Happened

Daré, which focuses on women's health, said Monday that its BV1 — a thermosetting hydrogel containing clindamycin phosphate 2% — has been given the Qualified Infectious Disease Product, or QIDP, designation by the FDA for the treatment of bacterial vaginosis in women.

BVI is a viscous liquid which goes through solution-to-gel transition using the body temperature as a trigger, which facilitates easy direction of the product to the site of infection.

"Receiving QIDP designation for DARE-BV1 for the treatment of BV is validation that BV is a serious infection for which current treatment options are inadequate," Daré CEO Sabrina Martucci Johnson said in a statement. 

Why It's Important

The clinical cure rates for currently approved products in bacterial vaginosis are about 37-39%, and the condition affects over 21 million among women ages 14-49, according to Daré.

The proof-of-concept study of BV1 showed an 86% clinical cure rate in the evaluable subjects at the test-of-cure visit after a single administration.

The QIDP designation is meant to incentivize development of antibacterial and antifungal drug products that treat serious or life-threatening infections. 

The designation confers: 

  • a five-year exclusivity extension, added to any exclusivity for which a QIDP qualifies upon FDA approval
  • The QIDP designation also makes the product candidate eligible for Fast Track designation and Priority Review

What's Next

Daré said it plans to start a late-stage study of BVI in about 250 women in the fourth quarter of 2019.

The company said it believes the Phase 3 study, if successful, would be sufficient for approval of BV1 to treat bacterial vaginosis.

Daré shares were rising 2.67% to 77 cents at the time of publication Monday. 

Related Links:

The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Posted-In: BV1Biotech News FDA Trading Ideas Best of Benzinga


Related Articles (DARE)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at